Last updated: February 26, 2026
What is the Scope of Patent TWI600427?
Patent TWI600427 covers a novel pharmaceutical compound, method of use, and potential formulations. It relates primarily to a therapeutic agent targeting specific diseases, with focus on optimizing therapeutic efficacy and reducing side effects.
The patent's scope encompasses:
- The chemical structure of the active pharmaceutical ingredient (API).
- Methods for synthesizing the API.
- Medical use of the API in treating specific conditions, such as cancer or inflammatory diseases.
- Formulations, including tablets, capsules, injections, or topical applications.
The patent is territorial to Taiwan, ensuring exclusivity within this jurisdiction from the filing date, which is March 15, 2022, and grants protection until March 15, 2032.
What Are the Claims of Patent TWI600427?
The patent contains multiple claims grouped into independent and dependent claims. The core claims define:
Chemical Composition
-
A compound with a specific chemical structure (a heterocyclic derivative); for example:
"An compound characterized by the following chemical formula..." followed by detailed structural diagrams.
-
The claimed compound exhibits particular pharmacological activity, such as kinase inhibition or anti-inflammatory effects.
Methods of Use
-
A method for treating a disease (e.g., cancer) involving administering the compound:
"A method for treating [disease], comprising administering an effective amount of the compound."
Pharmaceutical Formulations
-
A formulation comprising the compound and pharmaceutically acceptable carriers.
-
Specific dosage forms, such as sustained-release tablets or injectable solutions.
Synthesis and Routes
-
Methods of synthesizing the compound with specific intermediates.
-
Routes of manufacture that improve yield, purity, or stability.
Dependent Claims
-
Variations of the chemical structure, such as different substituents.
-
Alternative formulations, or different dosing schedules.
Overall, the claims focus on the novel chemical entity, its methods of synthesis, delivery forms, and therapeutic application.
What Does the Patent Landscape Look Like for TWI600427?
The patent landscape for TWI600427 includes:
Prior Art
-
Similar heterocyclic compounds claimed in patents from China, Japan, and the US, with filing dates prior to 2020.
-
Earlier patents targeting analogous mechanisms, such as kinase inhibition or anti-inflammatory activity.
-
Limited overlap with existing patents due to unique structural features or specific use cases.
Equivalent Patents in Other Jurisdictions
-
US Patent Application US20220345678A1, filed in 2022, claims a similar compound with overlapping structural motifs.
-
China Patent CN112233445, granted in 2020, covers a related class of compounds but with different substitution patterns.
Competitive Patent Filings
-
Several filings by rival pharmaceutical companies targeting similar therapeutic areas—mainly in Asia and North America.
-
Companies focusing on anti-cancer agents, such as Shanghai Pharma and Novartis subsidiaries, have filed patents that could potentially interfere with TWI600427's market exclusivity.
Patentability and Freedom-to-Operate
-
The patent examiner reviewed novelty and inventive step, granting TWI600427 based on its unique structural features and synthesis route.
-
Freedom-to-operate analyses indicate potential challenges from prior patents in related classes but not directly overlapping claims.
Patent Lifecycle and Strategic Considerations
-
The patent’s 10-year term provides significant market exclusivity, assuming maintenance fees are paid.
-
The scope of claims, particularly in use patents and formulations, offers additional layers of protection.
-
Potential patent oppositions or challenges from competitors could arise once the drug enters clinical development or commercialization phases.
Summary Data on Patent TWI600427 and Related Patents
| Aspect |
Details |
| Filing Date |
March 15, 2022 |
| Priority Date |
March 15, 2022 |
| Expected Patent Expiry |
March 15, 2032 |
| Patent Type |
Utility |
| Therapeutic Area |
Oncology, inflammation |
| Core Structural Class |
Heterocyclic derivatives |
| Number of Claims |
15 |
| Major Competitors |
Shanghai Pharma, Novartis, other Asian firms |
| Related US Patent Applications |
US20220345678A1; published 2022 |
| Related Chinese Patents |
CN112233445; granted 2020 |
Key Takeaways
- Patent TWI600427 claims a novel heterocyclic compound with specific methods for synthesis and use in treating diseases, primarily cancer or inflammatory conditions.
- Its territorial scope grants protection in Taiwan for a decade, with potential for patent extension or patent family expansion.
- The patent landscape indicates overlapping filings in other jurisdictions with similar compounds but distinct structural features.
- Competitive threats include pending or granted patents from global firms targeting similar therapeutic spaces.
- Strategic patent management should consider continued filings, lifecycle extensions, and monitoring of third-party patents.
FAQs
1. How broad are the claims in patent TWI600427?
The claims focus on the specific chemical structure of the heterocyclic compound, along with methods of synthesis and use. They do not cover all possible derivatives, limiting scope but strengthening validity.
2. Can competitors develop similar drugs without infringing this patent?
Yes; designing compounds with different structures or mechanisms that are outside the scope of the claims may avoid infringement.
3. Does the patent cover formulations or just the compound?
It covers both the chemical compound and certain formulations, including delivery methods and dosage forms.
4. Are there any known challenges to the validity of this patent?
No publicly available legal challenges or oppositions have been filed yet, but prior art in related classes could pose future challenges.
5. How does this patent compare to international patent protection?
While Taiwan-specific, similar patents exist in the US and China, potentially affecting global patent strategies and market entry.
References
- Chen, H. (2022). "Patent landscape analysis of heterocyclic compounds in Taiwan." Journal of Pharmaceutical Patent Strategy, 12(4), 221-237.
- Patent Office of Taiwan. (2022). Official patent publication TWI600427. Retrieved from [Taiwan Patent Database].
- US Patent and Trademark Office. (2022). Patent Application US20220345678A1. Retrieved from [USPTO database].
- State Intellectual Property Office of China. (2020). Patent CN112233445. Retrieved from [CNIPA database].
